You just read:

COSENTYX® - first Interleukin-17A inhibitor for psoriatic arthritis and ankylosing spondylitis approved by Health Canada(1)

News provided by

Novartis Pharmaceuticals Canada Inc.

Apr 27, 2016, 08:00 ET